Biden requests $503M increase for NCI, new funds for the Moonshot, $1B for ARPA-H in FY24

Arnold D. Kaluzny, longtime adviser to the NCI and health services researcher, dies at 87

Arnold Daniel “Arnie” Kaluzny, PhD, longtime adviser to NCI and an early pioneer and contributor to what is now known as health services research, died Oct. 29 at the age of 87.

November 21, 2025

Vol.51 No.43

By Donna M. O’Brien and Barnett Kramer

In Brief

Mount Sinai Tisch Cancer Center receives Comprehensive designation and funding from NCI

The Mount Sinai Tisch Cancer Center received the Comprehensive Cancer Center designation from NCI.

November 21, 2025

Vol.51 No.43

Conversation with The Cancer Letter Regulatory News

Richard Pazdur, a respected insider with a plan to reengineer FDA, steps in as CDER director

Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry.

Trump signs CR that funds government through Jan. 30, ending the longest shutdown in U.S. history

On the evening of Nov. 12, President Donald Trump signed a continuing resolution that officially ended the 43-day-long U.S. government shutdown that began on Oct. 1.

Trump administration and Cornell reach agreement to restore federal research funding

Cornell University has come to an agreement with the Trump administration that will unfreeze the university’s more than $250 million in interrupted federal research funding and “protect Cornell’s students from violations of federal civil rights laws, including from discrimination based on race, sex, or national origin, and promote America’s hardworking farming and rural communities” following accusations of antisemitism and discrimination in admissions.

November 14, 2025

Vol.51 No.42

By Jacquelyn Cobb and Claire Marie Porter

Cancer Policy

American Academy of Pediatrics: Leucovorin is not recommended for routine use in autistic children

The American Academy of Pediatrics does not recommend the routine use of leucovorin (folinic acid) for autistic children, according to the interim guidance issued by the physician group Oct. 31.

November 07, 2025

Vol.51 No.41

By Sara Willa Ernst

Biden requests $503M increase for NCI, new funds for the Moonshot, $1B for ARPA-H in FY24

YOU MAY BE INTERESTED IN

Arnold D. Kaluzny, longtime adviser to the NCI and health services researcher, dies at 87

Mount Sinai Tisch Cancer Center receives Comprehensive designation and funding from NCI

Richard Pazdur, a respected insider with a plan to reengineer FDA, steps in as CDER director

Trump signs CR that funds government through Jan. 30, ending the longest shutdown in U.S. history

Trump administration and Cornell reach agreement to restore federal research funding

American Academy of Pediatrics: Leucovorin is not recommended for routine use in autistic children

Renew today!

Subscriber content

Never miss an issue!

Login